Advanced Cell Technology Ready to File Independent New Drug Application for Stem Cell Based Program for Treating Retinal Diseases
March 15, 2009
The Journal of New England Technology reported last week that Advanced Cell Technology Inc is preparing to file an independent new drug application for its stem-cell-based program for treating retinal diseases in the second half of 2009 with the U.S. Food and Drug Administration.
It is necessary to file the IND before the company can proceed with its Phase 1 and Phase 2 clinical trials for retinal pigment epithelium. Advanced Cell estimated there are some 200 different retinal diseases that may be impacted by stem cell treatment, including macular degeneration.
Advanced Cell has secured $5 million in funding to file the IND application.
Read the full story.
You might also enjoy...
- Advanced Cell Technology Files Application for Trial to Treat Dry AMD With Human Embryonic Stem Cells
- Can ACTC’s Stem Cells be Used to Treat Severe Myopia?
- Stemedica Cell Technologies Announces Breakthrough Discovery in Use of Stem Cells for Treating Retinal Degeneration
- Advanced Cell Technology, OHSU Researchers Show Safety, Efficacy of Human Embryonic Stem Cell (hESC)-Derived Retinal Pigment Epithelium (RPE)
- First Clinical Results of Using Embryonic Stem Cells to Treat Eye Disease Published in The Lancet
Jump down to form below to submit your own comments